Stanley Laman Group Ltd. lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 4.9% during the 4th quarter, Holdings Channel reports. The firm owned 11,911 shares of the company’s stock after selling 617 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Eli Lilly and were worth $2,011,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. CRA Financial Services LLC lifted its holdings in shares of Eli Lilly and by 1.2% in the fourth quarter. CRA Financial Services LLC now owns 4,316 shares of the company’s stock valued at $729,000 after purchasing an additional 51 shares in the last quarter. Meridian Wealth Management LLC lifted its holdings in shares of Eli Lilly and by 2.9% in the fourth quarter. Meridian Wealth Management LLC now owns 1,887 shares of the company’s stock valued at $318,000 after purchasing an additional 53 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in shares of Eli Lilly and by 1.1% in the fourth quarter. Park Avenue Securities LLC now owns 5,091 shares of the company’s stock valued at $860,000 after purchasing an additional 55 shares in the last quarter. Kingfisher Capital LLC lifted its holdings in shares of Eli Lilly and by 2.0% in the fourth quarter. Kingfisher Capital LLC now owns 2,855 shares of the company’s stock valued at $482,000 after purchasing an additional 55 shares in the last quarter. Finally, HT Partners LLC lifted its holdings in shares of Eli Lilly and by 1.4% in the fourth quarter. HT Partners LLC now owns 4,428 shares of the company’s stock valued at $748,000 after purchasing an additional 61 shares in the last quarter. 75.59% of the stock is currently owned by institutional investors.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, January 11th. The shares were sold at an average price of $185.49, for a total value of $40,807,800.00. Following the completion of the sale, the insider now owns 111,003,815 shares of the company’s stock, valued at $20,590,097,644.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is owned by corporate insiders.
LLY stock traded up $1.82 on Tuesday, hitting $202.50. 28,721 shares of the company were exchanged, compared to its average volume of 4,843,328. Eli Lilly and Company has a twelve month low of $117.06 and a twelve month high of $218.00. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.36 and a quick ratio of 1.06. The business’s fifty day moving average is $195.97 and its two-hundred day moving average is $161.62. The stock has a market capitalization of $194.08 billion, a price-to-earnings ratio of 32.79, a price-to-earnings-growth ratio of 1.57 and a beta of 0.37.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Thursday, January 28th. The company reported $2.75 EPS for the quarter, topping the consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The firm had revenue of $7.44 billion during the quarter, compared to analyst estimates of $7.27 billion. During the same quarter in the prior year, the business posted $1.73 earnings per share. Eli Lilly and’s revenue for the quarter was up 21.7% compared to the same quarter last year. Equities research analysts expect that Eli Lilly and Company will post 7.56 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 10th. Stockholders of record on Friday, February 12th will be given a $0.85 dividend. The ex-dividend date of this dividend is Thursday, February 11th. This represents a $3.40 annualized dividend and a dividend yield of 1.68%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.74. Eli Lilly and’s dividend payout ratio is presently 56.29%.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It offers endocrinology products for diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and paediatric growth conditions. The company also provides neuroscience products for treating depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; migraine and episodic cluster headache; attention-deficit hyperactivity disorder; and schizophrenia.
Further Reading: Overbought
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.